Distinct genetic architectures and environmental factors associate with host response to the γ2-herpesvirus infections.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
31 07 2020
Historique:
received: 02 11 2019
accepted: 13 07 2020
entrez: 2 8 2020
pubmed: 2 8 2020
medline: 10 9 2020
Statut: epublish

Résumé

Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr Virus (EBV) establish life-long infections and are associated with malignancies. Striking geographic variation in incidence and the fact that virus alone is insufficient to cause disease, suggests other co-factors are involved. Here we present epidemiological analysis and genome-wide association study (GWAS) in 4365 individuals from an African population cohort, to assess the influence of host genetic and non-genetic factors on virus antibody responses. EBV/KSHV co-infection (OR = 5.71(1.58-7.12)), HIV positivity (OR = 2.22(1.32-3.73)) and living in a more rural area (OR = 1.38(1.01-1.89)) are strongly associated with immunogenicity. GWAS reveals associations with KSHV antibody response in the HLA-B/C region (p = 6.64 × 10

Identifiants

pubmed: 32737300
doi: 10.1038/s41467-020-17696-2
pii: 10.1038/s41467-020-17696-2
pmc: PMC7395761
doi:

Substances chimiques

Antibodies, Viral 0
Antigens, Viral 0
Capsid Proteins 0
Epstein-Barr Virus Nuclear Antigens 0
Epstein-Barr viral capsid antigen 0
HLA-DQ alpha-Chains 0
HLA-DQA1 antigen 0
EBV-encoded nuclear antigen 1 O5GA75RST7

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3849

Subventions

Organisme : Medical Research Council
ID : MR/S003711/2
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : Medical Research Council
ID : MR/S003711/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT090132
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : Wellcome Trust
ID : WT098051
Pays : United Kingdom

Références

Plummer, M. et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health 4, e609–e616 (2016).
pubmed: 27470177
De Flora, S. & La Maestra, S. Epidemiology of cancers of infectious origin and prevention strategies. J. Prev. Med. Hyg. 56, E15–E20 (2015).
pubmed: 26789827
de Sanjose, S. et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J. Infect. Dis. 199, 1449–1456 (2009).
pubmed: 19351262
Krithivas, A., Young, D. B., Liao, G., Greene, D. & Hayward, S. D. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J. Virol. 74, 9637–9645 (2000).
pubmed: 11000236 pmcid: 112396
Xu, D. et al. Epstein−Barr virus inhibits Kaposi’s sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J. Virol. 81, 6068–6078 (2007).
pubmed: 17376914 pmcid: 1900272
Jiang, Y., Xu, D., Zhao, Y. & Zhang, L. Mutual inhibition between Kaposi’s sarcoma-associated herpesvirus and Epstein−Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS ONE 3, e1569 (2008).
pubmed: 18253508 pmcid: 2215330
Spadavecchia, S., Gonzalez-Lopez, O., Carroll, K. D., Palmeri, D. & Lukac, D. M. Convergence of Kaposi’s sarcoma-associated herpesvirus reactivation with Epstein−Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J. Virol. 84, 10488–10500 (2010).
pubmed: 20686042 pmcid: 2950570
Horenstein, M. G. et al. Epstein−Barr virus latent gene expression in primary effusion lymphomas containing Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8. Blood 90, 1186–1191 (1997).
pubmed: 9242551
Sallah, N. et al. Genome-wide sequence analysis of Kaposi sarcoma-associated herpesvirus shows diversification driven by recombination. J. Infect. Dis. 218, 1700–1710 (2018).
pubmed: 30010810 pmcid: 6195662
Correia, S. et al. Sequence variation of Epstein−Barr virus: viral types, geography, codon usage, and diseases. J. Virol. https://doi.org/10.1128/JVI.01132-18 (2018).
Sallah, N. et al. Whole-genome association study of antibody response to Epstein−Barr virus in an African population: a pilot. Glob. Health Epidemiol. Genom. 2, e18 (2017).
pubmed: 29868224 pmcid: 5870407
Rubicz, R. et al. A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein−Barr virus nuclear antigen 1 (EBNA-1). PLoS Genet. 9, e1003147 (2013).
pubmed: 23326239 pmcid: 3542101
Hammer, C. et al. Amino acid variation in HLA class II proteins is a major determinant of humoral response to common viruses. Am. J. Hum. Genet. 97, 738–743 (2015).
pubmed: 26456283 pmcid: 4667104
Scepanovic, P. et al. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 10, 59 (2018).
pubmed: 30053915 pmcid: 6063007
Mbulaiteye, S. M. et al. Human herpesvirus 8 infection within families in rural Tanzania. J. Infect. Dis. 187, 1780–1785 (2003).
pubmed: 12751036
Guttman-Yassky, E. et al. Familial clustering of classic Kaposi sarcoma. J. Infect. Dis. 189, 2023–2026 (2004).
pubmed: 15143469
Plancoulaine, S. et al. Respective roles of serological status and blood specific antihuman herpesvirus 8 antibody levels in human herpesvirus 8 intrafamilial transmission in a highly endemic area. Cancer Res. 64, 8782–8787 (2004).
pubmed: 15574792
Plancoulaine, S. et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet 356, 1062–1065 (2000).
pubmed: 11009141
Kaasinen, E. et al. Nationwide registry-based analysis of cancer clustering detects strong familial occurrence of Kaposi sarcoma. PLoS ONE 8, e55209 (2013).
pubmed: 23365693 pmcid: 3554690
Jackson, C. C. et al. Kaposi sarcoma of childhood: inborn or acquired immunodeficiency to oncogenic HHV-8. Pediatr. Blood Cancer 63, 392–397 (2016).
pubmed: 26469702
Brown, E. E. et al. Host immunogenetics and control of human herpesvirus-8 infection. J. Infect. Dis. 193, 1054–1062 (2006).
pubmed: 16544245
Goedert, J. J. et al. Risk of classic Kaposi sarcoma with combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci: a population-based case-control study. J. Infect. Dis. 213, 432–438 (2016).
pubmed: 26268853
Alkharsah, K. R., Dedicoat, M., Blasczyk, R., Newton, R. & Schulz, T. F. Influence of HLA alleles on shedding of Kaposi sarcoma-associated herpesvirus in saliva in an African population. J. Infect. Dis. 195, 809–816, (2007).
pubmed: 17299710
Yang, D. et al. Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. Proc. Natl. Acad. Sci. USA 111, E4762–E4768 (2014).
pubmed: 25341731
Cornejo Castro, E. M. et al. Relationship between human leukocyte antigen alleles and risk of Kaposi’s sarcoma in Cameroon. Genes Immun. https://doi.org/10.1038/s41435-019-0077-9 (2019).
Asiki, G. et al. The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies. Int. J. Epidemiol. 42, 129–141 (2013).
pubmed: 23364209 pmcid: 3600628
Riha, J. et al. Urbanicity and lifestyle risk factors for cardiometabolic diseases in rural Uganda: a cross-sectional study. PLoS Med. 11, e1001683 (2014).
pubmed: 25072243 pmcid: 4114555
Labo, N. et al. Mutual detection of Kaposi’s sarcoma-associated herpesvirus and Epstein-Barr virus in blood and saliva of Cameroonians with and without Kaposi’s sarcoma. Int. J. Cancer https://doi.org/10.1002/ijc.32546 (2019).
Labo, N. et al. Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS Pathog. 10, e1004046 (2014).
pubmed: 24675986 pmcid: 3968157
Newton, R. et al. Kaposi sarcoma-associated herpesvirus in a rural Ugandan cohort, 1992−2008. J. Infect. Dis. 217, 263–269 (2018).
pubmed: 29099933
Heckerman, D. et al. Linear mixed model for heritability estimation that explicitly addresses environmental variation. Proc. Natl. Acad. Sci. USA 113, 7377–7382 (2016).
pubmed: 27382152
Gurdasani, D. et al. The African Genome Variation Project shapes medical genetics in Africa. Nature https://doi.org/10.1038/nature13997 (2014).
Gurdasani, D. et al. Uganda genome resource enables insights into population history and genomic discovery in Africa. Cell 179, 984–1002 e1036 (2019).
pubmed: 31675503
Masala, M. V. et al. Classic Kaposi’s sarcoma in Sardinia: HLA positive and negative associations. Int. J. Dermatol. 44, 743–745 (2005).
pubmed: 16135142
van der Kuyl, A. C. et al. An IL-8 gene promoter polymorphism is associated with the risk of the development of AIDS-related Kaposi’s sarcoma: a case-control study. AIDS 18, 1206–1208 (2004).
pubmed: 15166538
Brown, E. E. et al. A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. Cancer Epidemiol. Biomark. Prev. 14, 633–637 (2005).
Morris, A. P. Transethnic meta-analysis of genomewide association studies. Genet. Epidemiol. 35, 809–822 (2011).
pubmed: 22125221 pmcid: 3460225
Wang, X. et al. Comparing methods for performing trans-ethnic meta-analysis of genome-wide association studies. Hum. Mol. Genet. 22, 2303–2311 (2013).
pubmed: 23406875
Charles, B. A. et al. A genome-wide association study of serum uric acid in African Americans. BMC Med. Genomics 4, 17 (2011).
pubmed: 21294900 pmcid: 3045279
Maller, J. B. et al. Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat. Genet. 44, 1294–1301 (2012).
pubmed: 23104008 pmcid: 3791416
Morrison, B. J., Labo, N., Miley, W. J. & Whitby, D. Serodiagnosis for tumor viruses. Semin. Oncol. 42, 191–206 (2015).
pubmed: 25843726
Newton, R. et al. The sero-epidemiology of Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda. International journal of cancer. Int. J. Cancer 103, 226–232 (2003).
pubmed: 12455037
Pfeiffer, R. M. et al. Geographic heterogeneity of prevalence of the human herpesvirus 8 in sub-Saharan Africa: clues about etiology. Ann. Epidemiol. 20, 958–963 (2010).
pubmed: 21074111
Shebl, F. M. et al. Population-based assessment of kaposi sarcoma-associated herpesvirus DNA in plasma among Ugandans. J. Med. Virol. 85, 1602–1610 (2013).
pubmed: 23852686 pmcid: 3755768
Wakeham, K. et al. Parasite infection is associated with Kaposi’s sarcoma associated herpesvirus (KSHV) in Ugandan women. Infect. Agent Cancer 6, 15 (2011).
pubmed: 21962023 pmcid: 3197512
Nalwoga, A. et al. Association between malaria exposure and Kaposi’s sarcoma-associated herpes virus seropositivity in Uganda. Trop. Med. Int. Health 20, 665–672 (2015).
pubmed: 25611008 pmcid: 4390463
Stockdale, L. et al. Human cytomegalovirus epidemiology and relationship to tuberculosis and cardiovascular disease risk factors in a rural Ugandan cohort. PLoS ONE 13, e0192086 (2018).
pubmed: 29408860 pmcid: 5800673
Newton, R. et al. Determinants of Gammaherpesvirus shedding in saliva among Ugandan children and their mothers. J. Infect. Dis. 218, 892–900 (2018).
pubmed: 29762709 pmcid: 6093317
Wakeham, K. et al. Trends in Kaposi’s sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi’s sarcoma: a nested case-control study. Int. J. Cancer 136, 2822–2830 (2015).
pubmed: 25395177
Nalwoga, A. et al. Kaposi’s sarcoma-associated herpesvirus seropositivity is associated with parasite infections in Ugandan fishing communities on Lake Victoria islands. PLoS Negl. Trop. Dis. 13, e0007776 (2019).
pubmed: 31618208 pmcid: 6816576
Zaitlen, N. et al. Using extended genealogy to estimate components of heritability for 23 quantitative and dichotomous traits. PLoS Genet. 9, e1003520 (2013).
pubmed: 23737753 pmcid: 3667752
Rubicz, R. et al. Genome-wide genetic investigation of serological measures of common infections. Eur. J. Hum. Genet. 23, 1544–1548 (2015).
pubmed: 25758998 pmcid: 4613484
Zhou, Y. et al. Genetic loci for Epstein−Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis. Mult. Scler. J. https://doi.org/10.1177/1352458515626598 (2016).
Besson, C. et al. Strong correlations of anti-viral capsid antigen antibody levels in first-degree relatives from families with Epstein−Barr virus-related lymphomas. J. Infect. Dis. 199, 1121–1127 (2009).
pubmed: 19284285
Sitas, F. et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N. Engl. J. Med. 340, 1863–1871 (1999).
pubmed: 10369849
Cannon, M. J. et al. Risk factors for Kaposi’s sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 17, 215–222 (2003).
pubmed: 12545082
Yanez, A. A., Harrell, T., Sriranganathan, H. J., Ives, A. M. & Bertke, A. S. Neurotrophic factors NGF, GDNF and NTN selectively modulate HSV1 and HSV2 lytic infection and reactivation in primary adult sensory and autonomic neurons. Pathogens https://doi.org/10.3390/pathogens6010005 (2017).
Myoung, J. & Ganem, D. Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells. J. Clin. Investig. 121, 1130–1140 (2011).
pubmed: 21339648
Roshan, R. et al. T-cell responses to KSHV infection: a systematic approach. Oncotarget 8, 109402–109416 (2017).
pubmed: 29312617 pmcid: 5752530
Butler, L. M. et al. Kaposi’s sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3. J. Virol. 86, 7158–7166 (2012).
pubmed: 22532676 pmcid: 3416330
Sabbah, S. et al. T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. Blood 119, 2083–2092 (2012).
pubmed: 22234686
Thakker, S. et al. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits major histocompatibility complex class II expression by disrupting enhanceosome assembly through binding with the regulatory factor X complex. J. Virol. 89, 5536–5556 (2015).
pubmed: 25740990 pmcid: 4442538
Dilthey, A. et al. Multi-population classical HLA type imputation. PLoS Comput Biol. 9, e1002877 (2013).
pubmed: 23459081 pmcid: 3572961
Nunn, A. J. et al. Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort study. BMJ 315, 767–771 (1997).
pubmed: 9345167 pmcid: 2127535
Genomes Project, C. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet. 44, 955–959 (2012).
pubmed: 22820512 pmcid: 3696580
Dilthey, A. T., Moutsianas, L., Leslie, S. & McVean, G. HLA*IMP–an integrated framework for imputing classical HLA alleles from SNP genotypes. Bioinformatics 27, 968–972 (2011).
pubmed: 21300701 pmcid: 3065693
Zhou, X. & Stephens, M. Efficient multivariate linear mixed model algorithms for genome-wide association studies. Nat. Methods 11, 407–409 (2014).
pubmed: 24531419 pmcid: 4211878
McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
pubmed: 27268795 pmcid: 4893825
Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
pubmed: 20616382 pmcid: 2922887

Auteurs

Neneh Sallah (N)

The Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK. Neneh.Sallah@lshtm.ac.uk.
London School of Hygiene & Tropical Medicine, London, UK. Neneh.Sallah@lshtm.ac.uk.
London School of Hygiene & Tropical Medicine, London, UK. Neneh.Sallah@lshtm.ac.uk.

Wendell Miley (W)

Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.

Nazzarena Labo (N)

Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.

Tommy Carstensen (T)

The Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Segun Fatumo (S)

The Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
London School of Hygiene & Tropical Medicine, London, UK.
MRC/UVRI at the London School of Hygiene & Tropical Medicine, Entebbe, Uganda.

Deepti Gurdasani (D)

The Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
Queen Mary University London, London, UK.

Martin O Pollard (MO)

The Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Alexander T Dilthey (AT)

Institute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany.

Alexander J Mentzer (AJ)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.

Vickie Marshall (V)

Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.

Elena M Cornejo Castro (EM)

Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.

Cristina Pomilla (C)

The Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Elizabeth H Young (EH)

The Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Gershim Asiki (G)

African Population and Health Research Center, Nairobi, Kenya.

Martin L Hibberd (ML)

London School of Hygiene & Tropical Medicine, London, UK.

Manjinder Sandhu (M)

Department of Medicine, University of Cambridge, Cambridge, UK.

Paul Kellam (P)

Department of Infectious Diseases, Imperial College London, London, UK.
Kymab Ltd, Babraham Research Complex, Cambridge, UK.

Robert Newton (R)

MRC/UVRI at the London School of Hygiene & Tropical Medicine, Entebbe, Uganda.

Denise Whitby (D)

Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.

Inês Barroso (I)

The Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK. ines.barroso@exeter.ac.uk.
MRC Epidemiology Unit, University of Cambridge, Cambridge, UK. ines.barroso@exeter.ac.uk.
Exeter Centre of ExcEllence in Diabetes (ExCEED), University of Exeter Medical School, Exeter, UK. ines.barroso@exeter.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH